Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients

Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina

Agilent opens new customer experience center in Mumbai

The center brings together hands on technology demonstrations, application expertise, and commercial operations

Emcure Pharma reduces Poviztra starting dose price by 55% in India

The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country

Orca Bio’s Orca-T FDA review extended to July 2026

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio

Biogen bags FDA nod for high dose SPINRAZA in spinal muscular atrophy

The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions

Merck completes acquisition of JSR Life Sciences’ chromatography business

Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing

Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease

Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume

Kenvue unleashes science-driven skincare offensive at American Academy of Dermatology meet

The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection